Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
03 2020
Historique:
received: 24 07 2019
accepted: 23 10 2019
entrez: 13 3 2020
pubmed: 13 3 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Several registry-based analyses suggested a survival advantage for married versus single patients with pancreatic cancer. The mechanisms underlying the association of marital status and survival are likely multiple and complex and, therefore, may be obscured in analyses generated from large population-based databases. The goal of this research was to characterize this potential association of marital status with outcomes in patients with resected pancreatic cancer who underwent combined modality adjuvant therapy on a prospective clinical trial. This is an ancillary analysis of 367 patients with known marital status treated on NRG Oncology/RTOG 97-04. Survival analysis was performed using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model. Of 367 patients, 271 (74%) were married or partnered and 96 (26%) were single. Married or partnered patients were more likely to be male. There was no association between marital status and overall survival (OS) or disease-free survival (DFS) on univariate (hazard ratio [HR], 1.09 and 1.01, respectively) or multivariate analyses (HR, 1.05 and 0.98, respectively). Married or partnered male patients did not have improved survival compared with female or single patients. Ancillary analysis of data from NRG Oncology/RTOG 97-04 demonstrated no association between marital and/or partner status and OS or DFS in patients with resected pancreatic cancer who received adjuvant postoperative chemotherapy followed by concurrent external beam radiation therapy and chemotherapy. Clinical trial identification number. NCT00003216. Several population-based studies have shown an epidemiological link between marital status and survival in patients with pancreatic cancer. A better understanding of this association could offer an opportunity to improve outcomes through psychosocial interventions designed to mitigate the negative effects of not being married. Based on the results of this analysis, patients who have undergone a resection and are receiving adjuvant therapy on a clinical trial are unlikely to benefit from such interventions. Further efforts to study the association between marital status and survival should be focused on less selected subgroups of patients with pancreatic cancer.

Sections du résumé

BACKGROUND
Several registry-based analyses suggested a survival advantage for married versus single patients with pancreatic cancer. The mechanisms underlying the association of marital status and survival are likely multiple and complex and, therefore, may be obscured in analyses generated from large population-based databases. The goal of this research was to characterize this potential association of marital status with outcomes in patients with resected pancreatic cancer who underwent combined modality adjuvant therapy on a prospective clinical trial.
MATERIALS AND METHODS
This is an ancillary analysis of 367 patients with known marital status treated on NRG Oncology/RTOG 97-04. Survival analysis was performed using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model.
RESULTS
Of 367 patients, 271 (74%) were married or partnered and 96 (26%) were single. Married or partnered patients were more likely to be male. There was no association between marital status and overall survival (OS) or disease-free survival (DFS) on univariate (hazard ratio [HR], 1.09 and 1.01, respectively) or multivariate analyses (HR, 1.05 and 0.98, respectively). Married or partnered male patients did not have improved survival compared with female or single patients.
CONCLUSION
Ancillary analysis of data from NRG Oncology/RTOG 97-04 demonstrated no association between marital and/or partner status and OS or DFS in patients with resected pancreatic cancer who received adjuvant postoperative chemotherapy followed by concurrent external beam radiation therapy and chemotherapy. Clinical trial identification number. NCT00003216.
IMPLICATIONS FOR PRACTICE
Several population-based studies have shown an epidemiological link between marital status and survival in patients with pancreatic cancer. A better understanding of this association could offer an opportunity to improve outcomes through psychosocial interventions designed to mitigate the negative effects of not being married. Based on the results of this analysis, patients who have undergone a resection and are receiving adjuvant therapy on a clinical trial are unlikely to benefit from such interventions. Further efforts to study the association between marital status and survival should be focused on less selected subgroups of patients with pancreatic cancer.

Identifiants

pubmed: 32162826
doi: 10.1634/theoncologist.2019-0562
pmc: PMC7066692
doi:

Banques de données

ClinicalTrials.gov
['NCT00003216']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e477-e483

Subventions

Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States

Informations de copyright

© AlphaMed Press 2019.

Références

Ann Surg Oncol. 2011 May;18(5):1319-26
pubmed: 21499862
Oncology (Williston Park). 2009 Mar;23(3):288-95
pubmed: 19418830
J Gastrointest Cancer. 2015 Mar;46(1):9-20
pubmed: 25403828
Oncotarget. 2016 Apr 26;7(17):24880-7
pubmed: 27036036
Eur J Epidemiol. 2014 Aug;29(8):551-8
pubmed: 24407880
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Clin Oncol. 2013 Nov 1;31(31):3869-76
pubmed: 24062405
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Soc Sci Med. 2001 Feb;52(3):357-68
pubmed: 11330771
PLoS One. 2011;6(6):e21052
pubmed: 21698253
Demography. 2011 May;48(2):481-506
pubmed: 21526396
J Clin Oncol. 2001 Mar 15;19(6):1728-33
pubmed: 11251003

Auteurs

Marsha Reyngold (M)

Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Kathryn A Winter (KA)

NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.

William F Regine (WF)

University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA.

Ross A Abrams (RA)

Rush University Medical Center, Chicago, Illinois, USA.

Howard Safran (H)

Rhode Island Hospital, Providence, Rhode Island, USA.

John P Hoffman (JP)

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

Rex B Mowat (RB)

Toledo Community Hospital Oncology Program, Community Clinical Oncology Program, Toledo, Ohio, USA.

John P Hayes (JP)

Northwestern Memorial Hospital, Chicago, Illinois, USA.

Ivan L Kessel (IL)

University of Texas Medical Branch, Galveston, Texas, USA.

Thomas DiPetrillo (T)

Lifespan Cancer Institute, Providence, Rhode Island, USA.

Samir Narayan (S)

Michigan Cancer Research Consortium, Grand Rapid, Michigan, USA.

Yuhchyau Chen (Y)

University of Rochester, Rochester, New York, USA.

Edgar Ben-Josef (E)

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.

Guila Delouya (G)

Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

John H Suh (JH)

Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Joshua Meyer (J)

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

Michael G Haddock (MG)

Mayo Clinic, Rochester, New York, USA.

Marvin Feldman (M)

Sinai Hospital of Baltimore, Baltimore, Maryland, USA.

Rakesh Gaur (R)

Kansas City Community Clinical Oncology Program, Prairie Village, Kansas, USA.

Kathleen Yost (K)

Grand Rapids Community Clinical Oncology Program, Grand Rapids, Michigan, USA.

Richard A Peterson (RA)

St. Francis Regional Medical Center, Shakopee, Minnesota, USA.

David L Sherr (DL)

The Brooklyn Hospital Center, New York, New York, USA.

Jennifer Moughan (J)

NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.

Christopher H Crane (CH)

Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH